Information relating to the Extraordinary General Meeting of Diamyd Medical on April 22 regarding the proposed restructuring of the Diamyd Group

Provided that the Extraordinary General Meeting of Diamyd Medical AB to be held on April 22 resolves in favor of the proposed restructuring of the Diamyd Group, after which Diamyd Medical AB will be renamed Mertiva AB, the incoming Board of Directors in the future Mertiva AB plans to appoint Andreas Bergsten as the President at a statutory meeting following the General Meeting. The proposed restructuring entails, among other effects, that the subsidiary Diamyd Therapeutics AB will be distributed to shareholders and the intention is to list the company on NASDAQ OMX First North. The current